Deseret Mutual Benefit Administrators Grows Position in Kenvue Inc. (NYSE:KVUE)

Deseret Mutual Benefit Administrators boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 29.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,528 shares of the company’s stock after acquiring an additional 568 shares during the quarter. Deseret Mutual Benefit Administrators’ holdings in Kenvue were worth $54,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of KVUE. Kennon Green & Company LLC increased its position in shares of Kenvue by 0.9% in the fourth quarter. Kennon Green & Company LLC now owns 171,535 shares of the company’s stock valued at $3,662,000 after buying an additional 1,513 shares in the last quarter. Eubel Brady & Suttman Asset Management Inc. increased its position in shares of Kenvue by 0.4% in the fourth quarter. Eubel Brady & Suttman Asset Management Inc. now owns 961,138 shares of the company’s stock valued at $20,520,000 after buying an additional 4,086 shares in the last quarter. Morningstar Investment Management LLC increased its position in shares of Kenvue by 30.8% in the fourth quarter. Morningstar Investment Management LLC now owns 12,392 shares of the company’s stock valued at $265,000 after buying an additional 2,919 shares in the last quarter. First Bank & Trust increased its position in shares of Kenvue by 3.4% in the fourth quarter. First Bank & Trust now owns 94,234 shares of the company’s stock valued at $2,012,000 after buying an additional 3,127 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its position in shares of Kenvue by 2.9% in the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock valued at $15,846,000 after buying an additional 21,222 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on KVUE. Barclays dropped their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Citigroup dropped their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Stock Up 4.1 %

NYSE KVUE opened at $23.31 on Friday. The stock has a market cap of $44.68 billion, a PE ratio of 43.97, a P/E/G ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The business has a 50 day moving average price of $21.31 and a two-hundred day moving average price of $22.18. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.52%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.